ClinicalTrials.gg
Active, not recruitingNCT07462923Updated Oct 30, 2026

HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

A Phase 1 interventional study of HS-20093 for injection in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma, sponsored by Hansoh BioMedical R&D Company. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Updated Oct 30, 2026Now Active, not recruiting11 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.

This is a phase 1b, open-label, multi-center study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HS-20093 in patients with advanced gastric and gastroesophageal junction adenocarcinoma.

Read the detailed description

The first approximately 20 eligible participants who meet the inclusion criteria and do not meet the exclusion criteria will receive intravenous infusion of 8.0 mg/kg HS-20093 once every three weeks (Q3W). Treatment will continue until objective disease progression or other treatment discontinuation criteria are met.

Based on preliminary safety, efficacy, and pharmacokinetic data, the sponsor may decide whether subsequent participants will continue the current dosing regimen (8.0 mg/kg, Q3W), switch to a lower dose (e.g., 6.0 mg/kg, Q3W), a higher dose (e.g., 10.0 mg/kg, Q3W), or transition to a dosing frequency of once every two weeks (with a single dose not exceeding 6.0 mg/kg).

02

Conditions studied

  • Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Keywords

  • Gastric and Gastroesophageal Junction Adenocarcinoma
  • HS-20093
03

In context

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least age of 18 years at screening, with no restrictions on gender.
  2. Signed and dated Form.
  3. Participants with or cytologically confirmed locally advanced unresectable or GC/GEJC, who have failed, or intolerant to standard therapies.
  4. At least one extra according to 1.1.
  5. (ECOG) Performance Status of 0\~1.
  6. Estimated >12 weeks.
  7. Agree to provide fresh or .
  8. Good organ function.
  9. Female subjects must not be pregnant at screening or have evidence of non-.
  10. Men or women should be using adequate measures throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following:

    • Previous or current treatment with B7-H3 targeted therapy.
    • Previous or current treatment with topoisomerase I inhibitors.
    • Any cytotoxic chemotherapy, agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
    • Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
    • Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
    • Treatment with drugs that are predominantly strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.
    • Currently receiving drugs known to prolong or may cause torsade de pointe; or requiring treatment with these drugs during the study.
  2. Histology shows squamous cell carcinoma, undifferentiated carcinoma, or mixed tumors , such as adenosquamous carcinoma or other mixed tumors.
  3. Any unresolved toxicities from prior therapy greater than Grade 1 according to 5.0 or baseline status.
  4. Presence of pleural effusion/ascites requiring clinical intervention.
  5. Newly diagnosed without treatment, or brain metastases that have not achieved stability despite treatment; presence of or brainstem ; presence of spinal cord compression.
  6. History of other primary
  7. Evidence of cardiovascular risk.
  8. Severe, uncontrolled or active cardiovascular diseases.
  9. Severe or poorly controlled hypertension.
  10. Severe or poorly controlled diabetes.
  11. Poorly controlled cancer-related pain.
  12. The presence of active infectious diseases has been known: , and .
  13. Major surgery within 4 weeks prior to the first scheduled dose of HS-20093.
  14. Active infection requiring therapeutic intravenous antibiotics within 2 weeks prior to the first dose.
  15. bleeding symptoms or marked hemorrhagic tendency within 1 month prior to the first dose of HS-20093.
  16. Serious arterial or venous thromboembolic events occurring within 3 months prior to the first dose of HS-20093.
  17. Active tuberculosis.
  18. History of known interstitial pneumonia or immune-mediated pneumonitis.
  19. History of active or prior disease requiring systemic treatment.
  20. Severe malnutrition.
  21. Current hepatic encephalopathy, hepatorenal syndrome, or cirrhosis ≥ class B.
  22. Requires long-term therapy.
  23. Having undergone any major surgery within 4 weeks prior to the first dose.
  24. Vaccination within 4 weeks prior to the first dose of HS-20093.
  25. History of severe allergy.
  26. Previous history of serious neurological or mental disorders. Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator.
  27. Currently enrolled in or participating in any other clinical study involving investigational interventions or other types of interventional medical research.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HS-20093

    Participants will receive HS-20093

    Drug: HS-20093 for injection

Interventions

  • Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigators based on RECIST version 1.1\[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\]

    Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

Secondary outcomes

  1. PFS assessed by RECIST 1.1 criteria

    PFS was defined as the time from first dose or random assignment (if any) to PD or death from any cause

    Time frame: From the first dose up to PD or death,whichever came first, assessed up to 24 months.

  2. Unconfirmed ORR (uORR)

    The proportion of participants who achieve a CR or PR as assessed by the investigator according to the RECIST v1.1 criteria

    Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  3. Duration of response (DoR)

    the time from the date of first documented objective response (CR or PR as assessed by the investigator according to the RECIST v1.1 criteria) to the date of first documented PD or death (whichever occurs first).

    Time frame: From the first dose up to PD or death, whichever came first, assessed up to 24 months.

  4. Incidence and severity of adverse events (AEs)

    AE assessed by investigator exclusively related to subject's underlying disease or medical condition \[graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\]. Any untoward medical occurrence in a clinical study participant, whether or not considered related to the medicinal product. Incidence and severity of AEs are assessed according to vital signs, laboratory variables, physical examination, electrocardiogram, etc.

    Time frame: From the first dose until 90 days after the last dose

  5. Cmax of HS-20093

    The Cmax is the maximum observed drug concentration of HS-20093

    Time frame: At the end of Cycle 1 (each cycle is 21 days)"

  6. Tmax of HS-20093

    The Tmax is defined as time to reach maximum observed drug concentration of HS-20093

    Time frame: At the end of Cycle 1 (each cycle is 21 days)"

  7. AUC0-t of HS-20093

    The AUC0-t is defined as the area under the drug concentration-time curve during a dose interval time period(t) of HS-20093

    Time frame: At the end of Cycle 1 (each cycle is 21 days)"

  8. Incidence of anti-hs-20093 antibodies (ADAs)

    Serum samples were collected for the determination of anti-drug antibody (ADA) at designated time points

    Time frame: From the first dose until 90 days after the last dose

07

Study locations

12 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Mar 10, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 30, 2026
Sites
11 sites added
Show 11 added (11 China)
  • The First Hospital of China Medical University · Beijing, China
  • Fujian Medical University Union Hospital · Fuzhou, China
  • The First Affiliated Hospital of Xiamen University · Xiamen, China
  • The Fourth Hospital of Hebei Medical University · Shijiazhuang, China
  • Harbin Medical University Cancer Hospital · Harbin, China
  • Henan Cancer Hospital · Zhengzhou, China
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, China
  • Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • Hunan Cancer Hospital · Changsha, China
  • Shanxi Cancer Hospital · Taiyuan, China
  • West China Hospital, Sichuan University · Chengdu, China
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Active, not recruiting
    11 sites added
    Show 11 added (11 China)
    • The First Hospital of China Medical University · Beijing, China
    • Fujian Medical University Union Hospital · Fuzhou, China
    • The First Affiliated Hospital of Xiamen University · Xiamen, China
    • The Fourth Hospital of Hebei Medical University · Shijiazhuang, China
    • Harbin Medical University Cancer Hospital · Harbin, China
    • Henan Cancer Hospital · Zhengzhou, China
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, China
    • Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • Hunan Cancer Hospital · Changsha, China
    • Shanxi Cancer Hospital · Taiyuan, China
    • West China Hospital, Sichuan University · Chengdu, China
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07462923
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Jan 29, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risvutatug rezetecan

Start the discussion